SuperworthMyriad Genetics shares outstanding MYGN
Diluted shares outstanding, averaged over each quarter, from 2009.
- Latest quarter, to Jun 30, 2026
- 94.8M
- On a year earlier
- +2.5%
- more shares
Myriad Genetics had 94.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 2.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 93.5M | +3% |
| FY2024 | 90.9M | +5% |
| FY2023 | 86.4M | +6% |
| FY2022 | 81.2M | +1% |
| FY2021 | 80.1M | +7% |
| FY2020 | 74.6M | −1% |
| FY2020 | 75.4M | +1% |
| FY2019 | 74.8M | +3% |
| FY2018 | 72.9M | +6% |
| FY2017 | 68.9M | −7% |
| FY2016 | 74M | +2% |
| FY2015 | 72.6M | −7% |
| FY2014 | 77.7M | −6% |
| FY2013 | 82.7M | −4% |
| FY2012 | 86.2M | −2% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 94.8M | +2% | |
| Q1 FY26 | 93.7M | +3% | |
| Q4 FY25 | 93.5M | +3% | |
| Q3 FY25 | 93.1M | +2% | |
| Q2 FY25 | 92.5M | +2% | |
| Q1 FY25 | 91.4M | +2% | |
| Q4 FY24 | 90.9M | +5% | |
| Q3 FY24 | 90.9M | +11% | |
| Q2 FY24 | 90.6M | +11% | |
| Q1 FY24 | 89.9M | +11% | |
| Q4 FY23 | 86.4M | +6% | |
| Q3 FY23 | 81.9M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Myriad Genetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.